Compare AbCellera Biologics Inc (ABCL) vs Veritone Inc (VERI) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Veritone (VERI) trades at $1.36, up 3.82% on the day, but remains under significant pressure with a bearish technical signal and negative profitability. The company reported a net loss of $111.73 million in 2025, with a net income margin of -123.76%, while revenue declined slightly to $90 million in 2026. Multiple class-action lawsuits filed in July 2026 allege securities fraud related to improper revenue accounting, creating substantial legal overhangs.

The outlook is highly speculative; while the consensus price target of $5.25 implies significant upside, the stock faces severe fundamental challenges and legal risks. Investment opportunity hinges on successful business turnaround and resolution of litigation, but current financial performance and negative cash flow from operations present substantial downside risk.